Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wachovia Downgrades OSI Pharmaceuticals


Wachovia downgraded OSI Pharmaceuticals (OSIP) to underperform from market perform.

Analyst George Farmer tells salesforce despite providing overall survival benefit in NSCLC registration trial supporting last week's Tarceva approval, he believes variables concerning smoking history, tumor histology, and degrees of EGFR expression should effect physician bias. He says supportive data illustrated in the package insert indicates to him a similar concern by the FDA.

In addition to the concerns, he expects additional competitive pressure from the equivalent Iressa, and the more tolerable Alimta. He notes the Tarceva price tag is 20% below his estimate, and OSI Pharmaceutical gets a 50% net profit from the U.S. sales of drug.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus